4 completed, 1 not yet recruiting, 1 terminated. 3 Phase 3, 2 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow Sitagliptin placebo: new trials by email Literature Review of Sitagliptin placebo trials Research Report on Sitagliptin placebo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Disease-modifying Efficacy of Sitagliptin Therapy in Early-stage Parkinson's Disease Sitagliptin, Sitagliptin placebo - Parkinson Disease | Phase 2 | Not yet recruiting | Yonsei University | 160 | 2026-12-15 | 2026-09-10 |
| Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH DA-1241, Sitagliptin, DA-1241 Placebo - NON-ALCOHOLIC STEATOHEPATITIS | Phase 2 | Completed | NeuroBo Pharmaceuticals Inc. | 109 | 2023-09-14 | 2024-11-14 |
| Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) Semaglutide 0.5 mg, Semaglutide 1.0 mg, Sitagliptin placebo - Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | Completed | Novo Nordisk A/S | 868 | 2017-08-28 | 2021-03-02 |
| Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes Fasiglifam (TAK-875), Fasiglifam (TAK-875) Placebo, Sitagliptin - Diabetes Mellitus, Type 2 | Phase 3 | Terminated | Takeda | 96 | 2013-06-01 | 2015-09-28 |
| SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies Liraglutide, Sitagliptin, Exenatide - Type 2 Diabetes | Phase 4 | Completed | Amsterdam UMC, location VUmc | 70 | 2013-04-01 | 2015-12-09 |
| 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years Lixisenatide (AVE0010), Lixisenatide Placebo, Pen auto-injector - Type 2 Diabetes Mellitus | Phase 3 | Completed | Sanofi | 319 | 2009-08-01 | 2016-10-11 |
Diabetes Mellitus, Type 2 (4) · Diabetes Mellitus (1) · Non-alcoholic Fatty Liver Disease (1) · Parkinson Disease (1)
Amsterdam UMC, location VUmc (1) · NeuroBo Pharmaceuticals Inc. (1) · Novo Nordisk A/S (1) · Sanofi (1) · Takeda (1) · Yonsei University (1)
Ukraine (3) · United States (3) · Brazil (2) · Canada (2) · Peru (2) · Poland (2) · Russia (2) · South Africa (2) · Argentina (1) · Australia (1) · Chile (1) · China (1) · Croatia (1) · Germany (1) · Guatemala (1)
PMID 26586327, PMID 27038451, PMID 27451030, PMID 27585605, PMID 27627981, PMID 30880443, PMID 33074557, PMID 33429063, PMID 38236431